Preventative and therapeutic vaccines for cervical cancer

Expert Review of Vaccines

Volumn 2, Issue 4, 2003, Pages 495-516

  Roden, Richard ^b   Wu, T C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cervical cancer; Cytotoxic T lymphocyte and tumor immunology; Human papillomavirus; Immunotherapy; L2; Tumors specific antigens; Vaccine; Virus like particles

Indexed keywords

BACTERIAL VACCINE; BOVINE PAPILLOMAVIRUS L1 VACCINE; BOVINE PAPILLOMAVIRUS L2 VACCINE; CANCER VACCINE; CANINE PAPILLOMAVIRUS L1 VACCINE; CANINE PAPILLOMAVIRUS L2 VACCINE; CAPSID PROTEIN; COTTON TAIL RABBIT PAPILLOMAVIRUS L1 VACCINE; COTTON TAIL RABBIT PAPILLOMAVIRUS L2 VACCINE; DNA VACCINE; HUMAN PAPILLOMA VIRUS L1 VACCINE; HUMAN PAPILLOMAVIRUS L2 VACCINE; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; PROTEIN VACCINE; RNA VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS DNA; VIRUS VACCINE; VIRUS VECTOR;

CANCER PREVENTION; CARCINOGENESIS; DENDRITIC CELL; DNA DETERMINATION; GENOTYPE; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS; FEMALE; HUMANS; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA; VIRAL VACCINES;

EID: 0042734443     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.4.495     Document Type: Review

References (225)

1. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19 (1999). HPV as a necessary cause of cervical cancer.
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2, 342-350 (2002).
3. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl Cancer Inst. 87, 796-802 (1995). Definition of high-risk HPV types.
4. Koutsky LA, Holmes KK, Critchlow CW et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 327, 1272-1278 (1992).
5. Trus BL, Roden RB, Greenstone HL, Vrhel M, Schiller JT, Booy FP. Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 Å resolution. Nat. Struct Biol. 4, 413-420 (1997).
6. Roden RB, Greenstone HL, Kirnbauer R et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70, 5875-5883 (1996).
7. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67, 315-322 (1993).
8. Zhou J, Sun XY, Davies H, Crawford L, Park D, Frazer IH. Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology 189, 592-599 (1992).
9. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA 89, 12180-12184 (1992).
10. Sasagawa T, Pushko P, Steers G et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 206, 126-135 (1995).
11. Nardelli-Haefliger D, Roden RB, Benyacoub J et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect. Immun. 65, 3328-3336 (1997).
12. Breitburd F, Kirnbauer R, Hubbert NL et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69, 3959-3963 (1995). Neutralizing IgG mediate protection after VLP vaccination.
13. Suzich JA, Ghim SJ, Palmer-Hill FJ et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA 92, 11553-11557 (1995). Neutralizing IgG mediate protection after VLP vaccination.
14. Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J. Virol. 76, 9798-9805 (2002). Antibody-mediated protection after L2 vaccination.
15. De Bruijn ML, Greenstone HL, Vermeulen H et al. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250, 371-376 (1998).
16. Wu TC. Immunology of the human papilloma virus in relation to cancer. Curr. Opin. Immunol. 6, 746-754, (1994).
17. Halpert R, Fruchter RG, Sedlis A, Butt K, Boyce JG, Sillman FH. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet. Gynecol. 68, 251-258 (1986).
18. Laga M, Icenogle JP, Marsella R et al. Genital papillomavirus infection and cervical dysplasia - opportunistic complications of HIV infection. Int. J. Cancer 50, 45-48 (1992).
19. Schafer A, Friedmann W, Mielke M, Schwartlander B, Koch MA. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am. J. Obstet. Gynecol. 164, 593-599 (1991).
20. Brandsma JL. Animal models for HPV vaccine development. Papillomavirus Report 5, 105-111 (1994).
21. Selvakumar R, Borenstein LA, Lin YL, Ahmed R, Wettstein FO. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J. Virol. 69, 602-605 (1995).
22. Tagami H. Regression phenomenon of numerous flat warts - an experiment on the nature of tumor immunity in man. Int. J. Dermatol. 22, 570-571 (1983).
23. Benton C, Shahidullah H, Hunter JAA. Human papillomavirus in the immunosuppressed. In: Papillomavirus Report. 23-26 (1992).
24. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 9, 271-296 (1991).
25. van Kooten C, Banchereau J. Functional role of CD40 and its ligand. Int. Arch. Allergy Immunol. 113, 393-399 (1997).
26. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388, 782-787 (1997).
27. Pierre P, Turley SJ, Gatti E et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388, 787-792 (1997).
28. Austyn JM. New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med. 183, 1287-1292 (1996).
29. + T cells after gene gun immunization. J. Exp. Med. 188, 1075-1082 (1998).
30. Yuan H, Estes PA, Chen Y et al. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J. Virol. 75, 7848-7853 (2001).
31. Kirnbauer R, Chandrachud LM, O'Neil BW et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219, 37-44 (1996). Generation of neutralizing antibody after L1 VLP vaccination.
32. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with a polynucleotide vaccine. J. Infect. Dis. 173, 314-320 (1996). Demonstrating the potential of L1 naked DNA vaccination.
33. Sundaram P, Tigelaar RE, Brandsma JL. Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge. Vaccine 15, 664-671 (1997).
34. Stanley MA, Moore RA, Nicholls PK et al. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 19, 2783-2792 (2001).
35. Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J. Virol. 72, 8220-8229 (1998).
36. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michalek SM. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin b subunit. Infect. Immun. 64, 1272-1283 (1996).
37. Rose RC, Lane C, Wilson S, Suzich JA, Rybicki E, Williamson AL. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine 17, 2129-2135 (1999).
38. Lowe RS, Brown DR, Bryan JT et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J. Infect. Dis. 176, 1141-1145 (1997).
39. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 (2002). The first evidence of protection against natural transmission of oncogenic HPV after vaccination with L1 VLP.
40. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171, 1387-1398 (1995).
41. Harro CD, Pang YY, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl Cancer Inst. 93, 284-292 (2001). Safety and immunogenicity of HPV16 L1 VLP in patients.
42. Evans TG, Bonnez W, Rose RC et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183, 1485-1493 (2001). Safety and immunogenicity of HPV16 L1 VLP in patients.
43. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J. Virol. 70, 3298-3301 (1996).
44. Pastrana DV, Vass WC, Lowy DR, Schiller JT. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 279, 361-369 (2001).
45. Plummer M, Franceschi S. Strategies for HPV prevention. Virus Res. 89, 285-293 (2002).
46. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J. Virol. 72, 959-964 (1998).
47. Roden RB, Yutzy WHt, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270, 254-257 (2000). Evidence of subdominant cross-reactive neutralizing epitopes in L2.
48. Roden RB, Weissinger EM, Henderson DW et al. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J. Virol. 68, 7570-7574 (1994).
49. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WF. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J. Gen. Virol. 74, 945-953 (1993).
50. Christensen ND, Kreider JW, Kan NC, DiAngelo SL. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 181, 572-579 (1991). L2 has potential as a prophylactic vaccine antigen.
51. Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 187, 612-619 (1992).
52. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J. Virol. 73, 6188-6190 (1999). Definition of a cross-reactive neutralizing L2 peptide epitope currently being tested for immunogenicity in patients.
53. Kawana K, Kawana Y, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine 19, 1496-1502 (2001).
54. Lacey CJ, Thompson HS, Monteiro EF et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J. Infect. Dis. 179, 612-618 (1999).
55. Thompson HS, Davies ML, Watts MJ et al. Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A. Vaccine 16, 1993-1999 (1998).
56. Thompson HS, Davies ML, Holding FP et al. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 17, 40-49 (1999).
57. van der Burg SH, Kwappenberg KM, O'Neill T et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19, 3652-3660 (2001).
58. deJong A, O'Neill T, Khan AY et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20, 3456-3464 (2002).
59. Bonnez W, Kashima HK, Leventhal B et al. Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP). Virology 188, 384-387 (1992).
60. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. 23, 117-128 (1992).
61. Stoler MH, Wolinsky SM, Whitbeck A, Broker TR, Chow LT. Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes. Virology 172, 331-340 (1989).
62. Rudolf MP, Nieland JD, DaSilva DM et al. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol. Chem. 380, 335-340 (1999).
63. Ohlschlager P, Osen W, Dell K et al. Human papillomavirus type 1611 capsomeres induce 11-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J. Virol. 77, 4635-4645 (2003).
64. Crook T, Morgenstern JP, Crawford L, Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells cotransformed by HPV-16 plus EJ-ras. Embo J. 8, 513-519 (1989).
65. Zehbe I, Wilander E, Delius H, Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 58, 829-833 (1998).
66. Gao L, Chain B, Sinclair C et al. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J. Gen. Virol. 75, 157-164 (1994).
67. Boursnell ME, Rutherford E, Hickling JK et al. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14, 1485-1494 (1996).
68. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 rumor cells with 7 recombinant vaccinia viruses expressing E6 and E7. Virology 181, 62-69 (1991).
69. Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF et al. Treatment of established tumors 7 with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21-26 (1996). Describes the creation of an E6/E7-expressing tumor that has been widely adopted as a preclinical model for therapuetic vaccines against HPV.
70. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int. J. Cancer 78, 41-45 (1998).
71. Chen CH, Suh KW, Ji H, Choti MA, Pardoll DM, Wu TC. Antigen-specific immunotherapy for HPV-16 E7-expressing tumors grown in liver. J. Hepatology 33, 91-98 (2000).
72. Borysiewicz LK, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [SEECOMMENTS]. Lancet 347, 1523-1527 (1996). This is the first paper to describe the use of 8: an HPV vaccine using vaccinia vector in a human clinical trial.
73. Adams M, Borysiewicz L, Fiander A et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19, 2549-2556 (2001).
74. Kaufmann AM, Stern PL, Rankin EM et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 8, 3676-3685 (2002).
75. Wu T-C, Guarnieri FG, Staveley-O'Carroll KF et al. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc. Natl Acad. Sci. 92, 11671-11675 (1995). This is the first description of vaccine development using intracellular sorting signal to enhance antigen processing and vaccine potency.
76. Lamikanra A, Pan ZK, Isaacs SN, Wu TC, Paterson Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J. Virol. 75, 9654-9664 (2001).
77. He Z, Wlazlo AP, Kowalczyk DW et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 270, 146-161 (2000).
78. Li J, Sun Y, Garen A. Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model. Proc. Natl Acad. Sci. USA 99, 16232-16236 (2002).
79. Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. 60, 5456-5463 (2000).
80. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther. 2, 357-362 (1995).
81. Liu DW, Tsao YP, Kung JT et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol. 74, 2888-2894 (2000).
82. Xiong C, Levis R, Shen P, Schlesinger S, Rice CM, Huang HV. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243, 1188-1191 (1989).
83. Hariharan MJ, Driver DA, Townsend K et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J. Virol. 72, 950-958 (1998).
84. Berglund P, Quesada-Rolander M, Putkonen P, Biberfeld G, Thorstensson R, Liljestrom P. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res. Hum. Retroviruses 13, 1487-1495 (1997).
85. Ying H, Zaks TZ, Wang RF et al. Cancer therapy using a self-replicating RNA vaccine. Nat. Med. 5, 823-827 (1999).
86. Daemen T, Riezebos-Brilman A, Bungener L, Regts J, Dontje B, Wilschut J. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 21, 1082-1088 (2003).
87. Daemen T, Regts J, Holtrop M, Wilschut J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther. 9, 85-94 (2002).
88. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RF, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239, 389-401 (1997).
89. Eiben GL, Velders MP, Schreiber H et al. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res. 62, 5792-5799 (2002). Describes an E7-expressing tumor model suitable for HPV vaccine studies in HLA-A2 transgenic mice.
90. Polo JM, Belli BA, Driver DA et al. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc. Natl Acad. Sci. USA 96, 4598-4603 (1999).
91. Velders MP, McElhiney S, Cassetti MC et al. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 61, 7861-7867 (2001).
92. Cheng WF, Hung CF, Hsu KF et al. Cancer immunotherapy using sindbis virus replicon particles encoding a VP22-antigen fusion. Hum. Gene Ther. 13, 553-568 (2002).
93. Zhao KN, Sun XY, Frazer IH, Zhou J. DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 243, 482-491 (1998).
94. Touze A and Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res. 26, 1317-1323 (1998).
95. Rossi JL, Gissman L, Jansen K, Muller M. Assembly of infectious human papillomavirus type 16 virus-like particle in Saccharomyces cerevisae. Hum. Gene Ther. 11, 1165-1176 (2000).
96. Shi W, Liu J, Huang Y, Qiao L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J. Virol. 75, 10139-10148 (2001).
97. Roden RB, Day PM, Bronzo BK et al. Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. J. Virol. 75, 10493-10497 (2001).
98. Lenz P, Day PM, Pang YY et al. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166, 5346-5355 (2001). Addresses the mechanism of VLP immunogenicity.
99. Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 166, 5917-5924 (2001). Addresses the mechanism of VLP immunogenicity.
100. Villanueva MS, Sijts AJ, Pamer EG. Listeriolysin is processed efficiently into an MHC class I-associated epitope in Listeria monocytogenes-infected cells. J. Immunol. 155, 5227-5233 (1995).
101. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 167, 6471-6479 (2001). The first paper describing HPV vaccines using the Listeria vector.
102. Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int. J. Cancer 102, 629-637 (2002).
103. Darji A, Guzman CA, Gerstel B et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91, 765-775 (1997).
104. Krul MR, Tijhaar EJ, Kleijne JA et al. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol. Immunother. 43, 44-48 (1996).
105. Londono LP, Chatfield S, Tindle RW et al. Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen. Vaccine 14, 545-552 (1996).
106. Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, Nardelli-Haefliger D. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 279, 354-360 (2001).
107. Jabbar IA, Fernando GJ, Saunders N et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 18, 2444-2453 (2000).
108. Kast WM, Brandt RM, Drijfhout JW, Melief CJ. Human leukocyte antigen-A2. 1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J. Immunother 14, 115-120 (1993).
109. Ressing ME, Sette A, Brandt RM et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154, 5934-5943 (1995). Describes the characterization of several HLA-A2-restricted CTL epitopes from HPV-16 E6/E7.
110. b-restricted CTL epitope, as well as an HPV-transformed tumor cell that has been adopted by many researchers.
111. Rudolf MP Man S, Melief CJ, Sette A, Kast WM. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res. 7, 788s-795s (2001).
112. Bourgault Villada I, Beneton N, Bony C et al. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B 8 and determination of the HLA-B18-specific binding motif. Eur. J. Immunol. 30, 2281-2289 (2000).
113. Steller MA, Gurski KJ, Murakami M et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res. 4, 2103-2109 (1998).
114. Yoon H, Chung MK, Min SS et al. Synthetic peptides of human papillomavirus type 18 E6 harboring HLA-A2.1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors. Virus Res. 54, 23-29 (1998).
115. van Driel WJ, Ressing ME, Kenter GG et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 35, 946-952 (1999).
116. Muderspach L, Wilczynski S, Roman L et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 6, 3406-3416 (2000).
117. van der Burg SH, Ressing ME, Kwappenberg KM et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int. J. Cancer 91, 612-618 (2001).
118. Ressing ME, van Driel WJ, Brandt RM et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother 23, 255-266 (2000).
119. Fernando GJ, Stenzel DJ, Tindle RW, Merza MS, Morein B, Frazer IH. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine 13, 1460-1467 (1995).
120. Tindle RW, Croft S, Herd K et al. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin. Exp. Immunol. 101, 265-271 (1995).
121. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321-327 (1998).
122. Schmidt W, Buschle M, Zauner W et al. Cell-free tumor antigen peptide-based cancer vaccines. Proc. Natl Acad. Sci. USA 94, 3262-3267 (1997).
123. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342, 561-564 (1989).
124. Schild H, Deres K, Wiesmuller KH, Jung G, Rammensee HG. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur. J. Immunol. 21, 2649-2654 (1991).
125. Sarkar AK, Tortolero-Luna G, Nehete PN, Arlinghaus RB, Mitchell MF, Sastry KJ. Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16. Viral Immunol. 8, 165-174 (1995).
126. Srivastava PK. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods 12, 165-171 (1997).
127. Srivastava PK, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6, 728-732 (1994).
128. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8, 657-665 (1998).
129. Vierboom MP, Feltkamp MC, Neisig A et al. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J. Immunother 21, 399-408 (1998).
130. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl Acad. Sci. USA 93, 7855-7860 (1996).
131. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156, 3911-3918 (1996).
132. Toes RE, van der Voort EI, Schoenberger SP et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160, 4449-4456 (1998).
133. Hariharan K, Braslawsky G, Barnett RS et al. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int. J. Oncol. 12, 1229-1235 (1998).
134. De Bruijn ML, Schuurhuis DH, Vierboom MP et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res. 58, 724-731 (1998).
135. Gerard CM, Baudson N, Kraemer K et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 19, 2583-2589 (2001).
136. Schirmbeck R, Bohm W, Melber K, Reimann J. Processing of exogenous heat-aggregated (denatured) and particulate (native) hepatitis B surface antigen for class I-restricted epitope presentation. J. Immunol. 155, 4676-4684 (1995).
137. Berry JM, Palefsky JM. A review of human papillomavirus vaccines: from basic science to clinical trials. Front Biosci 8, S333-345 (2003). Useful review summarizing current HPV vaccine trials.
138. Suzue K, Zhou X, Hsen HN, Young RA. Heat shock fusion protects as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc. Natl Acad. Sci. USA 94, 13146-13151 (1997).
139. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. 121, 216-225 (2000).
140. Goldstone SE, Palefsky JM, Winnett MT, Neefe JR. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis. Colon Rectum 45, 502-507 (2002).
141. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362, 755-758 (1993).
142. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 153, 4775-4787 (1994).
143. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186, 1623-1631 (1997).
144. Roman M, Martin-Orozco E, Goodman JS et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3, 849-854 (1997).
145. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynudeotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl Acad. Sci. USA 94, 10833-10837 (1997).
146. Zwaveling S, Ferreira Mota SC, Nouta J et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358 (2002).
147. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17, 131-137 (1996).
148. Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267, 243-246 (1995).
149. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 153, 4925-4933 (1994).
150. Gromme M, Uytdehaag FG, Janssen H et al. Recycling MHC class I molecules and endosomal peptide loading. Proc. Natl Acad. Sci. USA 96, 10326-10331 (1999).
151. Greenstone HL, Nieland JD, de Visser KE et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl Acad. Sci. USA 95, 1800-1805 (1998). Describes characterization of an HPV-16 chimeric VLP capable of generating preventative and therapeutic vaccine effects in a preclinical model.
152. Peng S, Frazer IH, Fernando GJ, Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 240, 147-157 (1998).
153. Schafer K, Muller M, Faath S et al. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int. J. Cancer 81, 881-888 (1999).
154. Jochmus I, Schafer K, Faath S, Muller M, Gissmann L. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch. Med. Res. 30, 269-274 (1999).
155. Muller M, Zhou J, Reed TD et al. Chimeric papillomavirus-like particles. Virology 234, 93-111 (1997).
156. Robinson HL, Torres CA. DNA vaccines. Semin. Immunol. 9, 271-283 (1997).
157. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Ann. Rev. Immunol. 15, 617-648 (1997).
158. Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med. 184, 1555-1560 (1996).
159. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998).
160. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD, Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2, 1122-1128 (1996). Demonstrates that DNA delivered via gene gun is directly targeted to professional antigen presenting cells
161. Robinson HL. Nucleic acid vaccines: an overview. Vaccine 15, 785-787 (1997).
162. Chen C-H, Wang T-L, Hung C-F et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60, 1035-1042 (2000). Describes HPV DNA vaccine encoding antigen linked to heat shock protein to enhance vaccine potency.
163. Cheng WF, Hung CF, Chai CY et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 108, 669-678 (2001). Describes an HPV DNA vaccine able to generate antigen-specific immunity as well as antiangiogenic effects in a preclinical model.
164. Hung CF, Cheng WF, Hsu KF et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 61, 3698-3703 (2001).
165. Ji H, Wang T-L, Chen C-H et al. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Hum. Gene Ther. 10, 2727-2740, (1999).
166. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88, 223-233 (1997).
167. Osen W, Peiler T, Ohlschlager P et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 19, 4276-4286 (2001). Describes the use of an HPV DNA vaccine employing a VP22 strategy, as well as a shuffled E7 gene to alleviate concern of oncogenicity of E7.
168. Hung CF, Cheng WF, Chai CY et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J. Immunol. 166, 5733-5740 (2001). First paper to describe the use of VP22 intercellular spreading strategy for HPV DNA vaccine development.
169. Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Muller M. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 294, 47-59 (2002).
170. Harms JS, Ren X, Oliveira SC, Splitter GA. Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations. J. Virol. 74, 3301-3312 (2000).
171. Koptidesova D, Kopacek J, Zelnik V, Ross NL, Pastorekova S, Pastorek J. Identification and characterization of a cDNA clone derived from the Marek's disease tumour cell line RPL1 encoding a homologue of α-transinducing factor (VP16) of HSV-1. Arch. Virol. 140, 355-362 (1995).
172. Dorange F, El Mehdaoui S, Pichon C, Coursaget P, Vautherot JF. Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL49 (VP22) and UL48 (VP16) genes: high-level expression and characterization of MDV-1 VP22 and VP16. J. Gen. Virol. 81 Pt 9, 2219-2230. (2000).
173. Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J. Virol. 76, 2676-2682 (2002).
174. Kim TW, Hung CF, Ling M et al. Enhancing DNA vaccine potency by co-administration of DNA encoding antiapoptotic proteins. J. Clin. Invest. 112, 109-117 (2003). Describes an innovative strategy to prolong the life of dendritic cells in order to enhance HPV DNA vaccine potency.
175. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156, 238-245 (1996).
176. Corr M, Tighe H, Lee D et al. Costimulation provided by DNA immunization enhances antitumor immunity. J. Immunol. 159, 4999-5004 (1997).
177. Tuting T. The immunology of cutaneous DNA immunization. Curr. Opin. Mol. Ther. 1, 216-225 (1999).
178. Leachman SA, Tigelaar RE, Shlyankevich M et al. Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus-rabbit model. J. Virol. 74, 8700-8708 (2000).
179. Tan J, Yang NS, Turner JG et al. Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response. Cancer Gene Ther. 6, 331-339 (1999).
180. Velders MP, Weijzen S, Eiben GL et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 166, 5366-5373 (2001).
181. Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJ, Frazer IH. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20, 862-869 (2001).
182. Shi W, Bu P, Liu J, Polack A, Fisher S, Qiao L. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J. Virol. 73, 7877-7881 (1999).
183. Liu WJ, Gao F, Zhao KN et al. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology 301, 43-52 (2002). This paper describes the enhancement of DNA vaccine potency using a codon-modified HPV gene.
184. Cid-Arregui A, Juarez V, zur Hausen H. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J. Virol. 77, 4928-4937 (2003).
185. Klencke B, Matijevic M, Urban RG et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res. 8, 1028-1037 (2002). Reports the first therapeutic HPV DNA vaccine trial.
186. Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljestrom P. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 16, 562-565 (1998).
187. Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 60, 51-55 (2000).
188. Cheng WF, Hung CF, Hsu KF et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/ lysosomal compartments. Hum. Gene Ther. 12, 235-252. (2001).
189. Cheng WF, Hung CF, Chai CY et al. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J. Immunol. 166, 6218-6226 (2001).
190. Cheng WF, Hung CF, Chai CY et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J. Virol. 75, 2368-2376. (2001).
191. Hsu KF, Hung KF, Cheng WF, He L, Ling MF, Wu TC. Enhancement of suicidal DNA vaccine potency by linkage of antigen gene to an HSP70 gene. (manuscript in preparation) (2000).
192. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 106, 263-266 (2001).
193. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. Emphasis Tumor Immunol. 18, 86-94 (1995).
194. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 15, 94-103 (1997).
195. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1, 1297-1302 (1995).
196. + T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res. 59, 1184-1187 (1999).
197. Doan T, Herd KA, Lambert PF, Fernando GJ, Street MD, Tindle RW. Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization. Cancer Res. 60, 2810-2815 (2000).
198. Liu Y, Chiriva-Internati M, Grizzi F et al. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther. 8, 948-957 (2001).
199. Chiriva-Internati M, Liu Y, Salati E et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur. J. Immunol. 32, 30-38 (2002).
200. Arthur JF, Butterfield LH, Roth MD et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4, 17-25 (1997).
201. Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur. J. Immunol. 27, 2702-2707 (1997).
202. Wang T-L, Ling M, Shih I-M et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther. 7, 726-733 (2000).
203. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J. Biomed Sci. 5, 231-252 (1998).
204. Hallez S, Detremmerie O, Giannouli C et al. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int. J. Cancer 81, 428-437 (1999).
205. Bubenik J, Simova J, Hajkova R et al. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int J. Oncol. 14, 593-597 (1999).
206. Chang EY, Chen CH, Ji H et al. Antigen-specific cancer immunotherapy using an GM-CSF secreting allogeneic tumor cell-based vaccine. Int. J. Cancer 86, 725-730 (2000).
207. Chen CH, Wang TL, Hung CF, Pardoll DM, Wu TC. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 18, 2015-2022 (2000).
208. Kowalczyk DW, Wlazlo AP, Shane S, Ertl HC. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. Vaccine 19, 3583-3590 (2001).
209. Christensen ND, Han R, Cladel NM, Pickel MD. Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences. Antimicrob. Agents Chemother. 45, 1201-1209 (2001).
210. Christensen ND, Pickel MD, Budgeon LR, Kreider JW. In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. Antiviral Res. 48, 131-142 (2000).
211. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med. 191, 961-976 (2000).
212. Steller MA. Human papillomavirus, it's genes... and cancer vaccines. Cancer Cell 3, 74 (2003).
213. Stanley MA. Human papillomavirus vaccines. Curr. Opin. Mol. Ther. 4, 15-22 (2002).
214. Breitburd F, Coursaget P. Human papillomavirus vaccines. Semin. Cancer Biol. 9, 431-444 (1999).
215. Bell JA, Sundberg JP, Ghim SJ, Newsome J, Jenson AB, Schlegel R. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology 62, 194-198 (1994).
216. Chandrachud SM, Grindlay GJ, McGarvie GM et al. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology 211, 204-208 (1995).
217. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J. Virol. 70(2), 960-965 (1996).
218. Gaukroger JM, Chandrachud LM, O'Neil BW, Grindlay GJ, Knowles G, Campo MS. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J. Gen. Virol. 77(Pt 7), 1577-1583 (1996).
219. Jansen KU, Rosolowsky M, Schultz LD et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13(16), 1509-1514 (1995).
220. Jarrett WF, O'Neil BW, Gaukroger JM, Smith KT, Laird HM, Campo MS. Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types. Vet. Rec. 126(19), 473-475 (1990).
221. Jarrett WF, Smith KT, O'Neil BW et al. Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 184(1), 33-42 (1991).
222. Kirnbauer R, Chandrachud LM, O'Neil BW et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219(1), 37-44 (1996).
223. Zhang LF, Zhou J, Chen S et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18(11-12), 1051-1058 (2000).
224. Kawana K, Yasugi T, Kawana Y, Yosikawa H, Kanda T, Taketani Y. Safety and immunogenicity of a peptide containing the cross neutralization epitope of HPV 16 L2 in nasal immunization of adult volunteers. 20th International Papillomavirus Conference, Paris, France. Abstract O103 (2000).
225. Villa L, Costa R, Petta C et al. A dose ranging safety and immunogenicity study of a quadrivalent HPV (Types 4/11/16/18) L1 VLP vaccine in women. 20th International Papillomavirus Conference, Paris, France. (2000) (Abstract 0099).